glp-1 obesity drug news oct 21 2025 New Daily Weight Loss Pill Aims to Take on Ozempic Obesity GLP-1 Market

New Jersey granted full practice authority to NPs in 2022, meaning NPs can evaluate, diagnose, and prescribe independently without physician oversight

Effects of somatostatin on plasma glucose and glucagon levels in human diabetes mellitus

ASCVD, atherosclerotic cardiovascular disease

Starting a GLP-1 for RA is a clinical decision that should account for your disease activity, your other conditions, and your goals

Morgan may be restricted from updating information contained in this communication for regulatory or other reasons

GLP-1 receptor agonists obesity drugs market captured the largest revenue share of 81% in 2024 within North America, driven by high obesity prevalence, early drug approvals, and robust healthcare infrastructure